Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05866991
Recruiting Observational

Cohort of Patients Suffering From Major Depressive Episode With Evaluation of Sleep, Circadian Rhythms and Psychiatric Disorders

NCT05866991 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Started
2023-02-01
Last updated
2026-08-12

Condition(s) studied

Major Depressive Episode

Study summary

Despite international efforts to identify biomarkers of depression, none has been transferred to clinical practice, neither for diagnosis, evolution, nor therapeutic response. This led us to build a French national cohort (through the clinical and research network named SoPsy within the French biological psychiatry society (AFPBN) and sleep society (SFRMS)), to better identify markers of sleep and biological rhythms and validate more homogeneous subgroups of patients, but also to specify the manifestations and pathogeneses of depressive disorders.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Individuals with depressive episode characterized according to the DSM-5 criteria regardless of the associated characteristics and comorbidities. * Adult and child * Affiliated to a social security Exclusion Criteria: * don't understand or read french * Medical condition incompatible with administration of questionnaire * impossibility to give informed decision (subject in an emergency condition, etc.)

Primary outcome measure(s)

  • amount of REM sleep — at inclusion
    during the polysomnography, amount of REM sleep (in minutes)

Trial sites (1)

FacilityCityRegionStatus
Hôpital Bichat Claude Bernard Paris Paris Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer Recruiting
New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study Recruiting
Primitive Immunodeficiency, Intrauterine Devices and Menstrual Hygiene Products Recruiting
Screening of Patients With Hepatic Fibrosis or Cirrhosis B and C Recruiting
Periodontitis and Inflammation: Study on Biological Samples Recruiting

Other trials for the same condition

Metabolomics During ElectroConvulsivoTherapy Recruiting
Signature Response to Light Therapy in Unipolar and Bipolar Major Depressive Episode (MDE) Recruiting
Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode Recruiting
Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05866991 on ClinicalTrials.gov ↗ ← All trials in France